Staging and Evaluation of the Patient with Lymphoma

Hematology/Oncology Clinics of North America

Volumn 22, Issue 5, 2008, Pages 825-837

  Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Hodgkin lymphoma; Non Hodgkin's lymphoma; PET Scan; Response criteria

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ANAMNESIS; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER STAGING; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DNA MICROARRAY; DRUG ABSORPTION; DRUG UPTAKE; FAMILY HISTORY; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HUMAN; LABORATORY TEST; LARGE CELL LYMPHOMA; LYMPH NODE HYPERPLASIA; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; NONHODGKIN LYMPHOMA; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SPLENOMEGALY; STEM CELL TRANSPLANTATION; TREATMENT PLANNING; TREATMENT RESPONSE;

HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 54049090463     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.07.015     Document Type: Review

References (67)

1. Cheson B.D. Hodgkin's disease, alcohol and vena caval obstruction. JAMA 239 (1978) 23-24
2. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17 (1999) 1244-1253
3. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
4. Grillo-López A.J., Cheson B.D., Horning S.J., et al. Response criteria for NHL: importance of "normal" lymph node size and correlations with response rates. Ann Oncol 11 (2000) 399-408
5. Surbone A., Longo D.L., DeVita Jr. V.T., et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 6 (1988) 1832-1837
6. Radford J.A., Cowan R.A., Flanagan M., et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 6 (1988) 940-946
7. Bangerter M., Moog F., Buchmann I., et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 9 (1998) 1117-1122
8. 18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 19 (2001) 414-419
9. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102 (2003) 53-59
10. Spaepen K., Stroobants S., Dupont P., et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13 (2002) 1356-1363
11. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 86 (2001) 266-273
12. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94 (1999) 429-433
13. Jerusalem G., Beguin Y., Najjar F., et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 12 (2001) 825-830
14. Jerusalem G., Warland V., Najjar F., et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 20 (1999) 13-20
15. Zinzani P.L., Magagnoli M., Chierichetti F., et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 10 (1999) 1141-1143
16. 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98 (2001) 2930-2934
17. Naumann R., Vaic A., Beuthien-Baumann B., et al. Prognostic value of popsitron emission tomography in the evalaution of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 115 (2001) 793-800
18. Kostakoglu L., Leonard J.P., Kuji I., et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 94 (2002) 879-888
19. Naumann R., Beuthien-Baumann B., Reiss A., et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 90 (2004) 620-625
20. Munker R., Glass J., Griffeth L.K., et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 15 (2004) 1699-1704
21. Mikhaeel N.G., Hutchings M., Fields P.A., et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16 (2005) 1514-1523
22. Juweid M., Wiseman G.A., Vose J.M., et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop criteria (IWC) and 18F-fluorodeoxyglucose positron emission tomography (PET). J Clin Oncol 23 (2005) 4652-4661
23. 18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106 (2005) 1376-1381
24. Hutchings M., Loft A., Hansen M., et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91 (2006) 482-489
25. Querellou S., Valette F., Bodet-Milin C., et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 85 (2006) 759-767
26. Gallamini A., Rigacci L., Merli F., et al. Predictive value of positron emission tomography performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91 (2006) 475-481
27. Hutchings M., Loft A., Hansen M., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59
28. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus recommendations of the Imaging Subcommittee of the International Harmonization Project in Lymphoma. J Clin Oncol 25 (2007) 571-578
29. Seam P., Juweid M.E., and Cheson B.D. The role of FDG-PET scans in patients with lymphoma. Blood 110 (2007) 3507-3516
30. Carbone P.P., Kaplan H.S., Musshoff K., et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31 (1971) 1860-1861
31. Newman J.S., Francis J.R., Kaminski M.S., et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 190 (1994) 111-116
32. Thill R., Neuerburg J., Fabry U., et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 36 (1997) 234-239
33. Moog F., Bangerter M., Diederichs C.G., et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]-D-glucpse (FDG) PET in nodal staging. Radiology 203 (1997) 795-800
34. Moog F., Bangerter M., Diederichs C.G., et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206 (1998) 475-481
35. Buchmann I., Reinhardt M., Elsner K., et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91 (2001) 889-899
36. Blum R.H., Seymour J.F., Wirth A., et al. Frequent impact of [18F] Fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 4 (2004) 43-49
37. Partridge S., Timothy A., O'Doherty M.J., et al. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 11 (2000) 1273-1279
38. Weihrauch M.R., Re D., Bischoff S., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 81 (2002) 20-25
39. Menzel C., Dobert N., Mitrou P., et al. Positron emission tomography for the staging of Hodgkin's lymphoma-increasing the body of evidence in favor of the method. Ann Oncol 41 (2002) 430-436
40. Schaefer N.G., Hany T.F., Taverna C., et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?. Radiology 232 (2004) 823-829
41. 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104 (2005) 1066-1074
42. Moog F., Bangerter M., Kotzerke J., et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. Blood 16 (1998) 603-609
43. Carr R., Barrington S.F., Madan B., et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91 (1998) 3340-3346
44. Pakos E.E., Fotopoulos A.D., and Ioannidis J.P. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46 (2005) 958-963
45. Rodriguez-Vigil B., Gomez-Leon N., Pinilla I., et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 47 (2006) 1643-1648
46. Tatsumi M., Cohade C., Nakamoto Y., et al. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 237 (2005) 1038-1045
47. Kwee T.C., Kwee R.M., and Nievelstein R.A. Imaging in staging of malignant lymphoma: a systematic review. Blood 111 (2008) 504-516
48. La Fougere C., Hundt W., Brockel N., et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nuclear Med Mol Imaging 33 (2006) 1417-1425
49. Pfistner B., Diehl V., and Cheson B. International harmonization of trial parameters in malignant lymphoma. Eur J Haematol Suppl 66 (2005, July) 53-54
50. 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nuclear Medicine Communications 26 (2005) 689-694
51. Zinzani P.L., Tani M., Fanti S., et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 17 (2006) 1296-1300
52. Kostakoglu L., Goldsmith S.J., Leonard J.P., et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107 (2006) 2678-2687
53. Gallamini A., Hutchings M., Rigacci L., et al. Early interim 2-[18F]fluoro-2-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25 (2007) 3746-3752
54. Moskowitz C., Hamlin P.A., Horwitz S.M., et al. Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL. Blood 108 (2006) 16:[abstract 532]
55. Hoppe R.T., Advani R.H., Bierman P.J., et al. Hodgkin disease/lymphoma. Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 4 3 (2006) 210-230
56. Zelenetz A.D., Advani R.H., Buadi F., et al. Non-Hodgkin's lymphoma: Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 4 3 (2006) 258-310
57. Weeks J.C., Yeap B.Y., Canellos G.P., et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 9 (1991) 1196-1203
58. Oh Y.K., Ha C.S., Samuels B.I., et al. Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. Radiology 210 (1999) 483-486
59. Foltz L.M., Song K.W., and Connors J.M. Who actually detects relapse in Hodgkin lymphoma: patient or physician. Blood 104 part 1 (2004) 853-854 a [abstract 3124]
60. Liedtke M., Hamlin P.A., Moskowitz C.H., et al. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 17 (2006) 909-913
61. Jerusalem G., Beguin Y., Fassotte M.F., et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 14 (2003) 123-130
62. Zinzani P.L., Stefoni V., Ambrosini V., et al. FDG-PET in the serial assessment of patients with lymphoma in complete remission. Blood 110 part 1 (2007) 71 a [abstract 216]
63. Hoffmann M., Kletter K., Diemling M., et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 10 (1999) 1185-1189
64. Elstrom R., Guan L., Baker G., et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101 (2003) 3875-3876
65. Karam M., Novak L., Cyriac J., et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107 (2006) 175-183
66. Hoffmann M., Wöhrer S., Becherer A., et al. 18F-fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol 17 (2006) 1761-1765
67. Lewis P.J., and Salama A. Uptake of fluorine-18-flouorodeoxyglucose in sarcoidosis. J Nucl Med 35 (1994) 1647-1649